Publication: Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting
2
Issued Date
2021-04-01
Resource Type
ISSN
17581052
09564624
09564624
Other identifier(s)
2-s2.0-85100457687
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of STD and AIDS. Vol.32, No.5 (2021), 421-426
Suggested Citation
Jaruwan Tiarukkitsagul, Somnuek Sungkanuparph Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting. International Journal of STD and AIDS. Vol.32, No.5 (2021), 421-426. doi:10.1177/0956462420972855 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78326
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting
Author(s)
Other Contributor(s)
Abstract
Cardiovascular disease has become an important health problem in people living with HIV (PLHIV) who receive antiretroviral therapy (ART). Atherosclerotic cardiovascular disease (ASCVD) risk score is a non-invasive tool to estimate the 10-year risk for ASCVD. A cross-sectional study was conducted among PLHIV receiving ART in a resource-limited setting, in order to assess the 10-year ASCVD risk between PLHIV receiving first-line and second-line ART. Of 460 participants with a mean age of 51.2 years, 262 (57.0%) were men. The mean duration of HIV infection was 14.7 years and the mean CD4 cell count was 509 cells/μL. Of all, 345 participants were receiving first-line ART and 115 were receiving second-line ART. The median 10-year ASCVD risk was 3.0% and 5.1% in the first-line and second-line ART groups, respectively (p = 0.029). The prevalence of a high 10-year ASCVD risk (≥20%) was significantly higher in the second-line ART group (3.5% vs 0.9%, p = 0.048). In multivariate analysis, receiving second-line ART was significantly associated with intermediate to high 10-year ASCVD risk (OR = 2.952; 95% CI, 1.656–6.997; p = 0.015). Atherosclerotic cardiovascular disease risk should be assessed in PLHIV, particularly those who receive second-line ART.